A to Z of investigational drugs

Drugs in the pipeline.

  • 2248761 (IDX899, GSK2248761)

    2248761 (formerly IDX899, GSK 2248761) is a non-nucleoside reverse transcriptase inhibitor in development by ViiV Healthcare, a specialist HIV company established by GlaxoSmithKline (GSK) and Pfizer.  In vitro

  • AMD070

    AMD070 is an investigational drug belonging to a new class of drugs known as CXCR4 inhibitors. It stops the process of HIV attachment and entry into CD4

  • Apricitabine (AVX754, SPD754)

    Apricitabine is a nucleoside reverse transcriptase inhibitor that is active against the M184V mutation and to other thymidine-associated mutations. It interferes with the process of HIV replication by imitating the nucleosides, or building

  • Bevirimat (PA-457 or MPC-4326)

    Bevirimat is the first experimental HIV maturation inhibitor. Development of bevirimat has been halted by its developer, Myriad Genetics.Maturation inhibitors reduce HIV viral load by

  • Cobicistat

    Gilead Sciences is conducting human studies of a product that could replace ritonavir as an antiretroviral boosting agent in some fixed-dose combinations. Cobicistat, formerly known

  • CTP-518

    CTP-518 is a novel HIV protease inhibitor from Concert Pharmaceuticals that replaces certain key hydrogen atoms of atazanavir with deuterium, a heavier, non-radioactive relative of

  • Elvitegravir (GS 9137)

    Elvitegravir (formerly GS 9137 and JTK-303) is a promising integrase inhibitor in late clinical development by Gilead Sciences. When studied in treatment-experienced patients with extensive drug resistance, viral load was

  • Elvucitabine (ACH-126)

    Elvucitabine (formerly, ACH-126) is a cytosine analogue similar to 3TC (Epivir) and FTC (Emtriva). It is being developed by Achillion Pharmaceuticals. Interim 48-week data from a phase II trial in treatment-naive

  • GS-8374 (TMC-126)

    GS-8374 (formerly TMC-126) is a protease inhibitor being developed by Gilead Sciences. It adds a phosphonate group onto a protease inhibitor; the corresponding prodrug is able

  • GSK-572

    S/GSK1349572, or GSK-572 for short, is a second-generation integrase inhibitor being developed jointly by Shionogi of Japan and ViiV Healthcare.Laboratory and early clinical studies showed that GSK-572

  • HGS004

    HGS004 is a human immunoglobulin (Ig) G4 monoclonal antibody against CCR5 that is being developed by Quest Clinical Research. HGS004 binds to and inhibits the activity of

  • INCB009471

    INCB009471, an investigational CCR5 antagonist, appears to be potent and well tolerated, according to results of a small phase IIa study presented in 2007. The

  • Minocycline

    Minocycline is an antibiotic that has been used since the 1970s for treating acne. Reports now indicate that minocycline effectively targets infected immune cells in

  • PPL-100

    PPL-100 is a protease inhibitor drug developed by Ambrilia. The drug was licensed to Merck until 2008 when it was returned to Ambrilia. It is currently

  • PRO 140

    PRO 140, developed by Progenics Pharmaceuticals, is a CCR5 monoclonal antibody that binds to the extracellular domain rather than the transmembrane pocket. In a phase II dose-ranging

  • Racivir

    Racivir is an experimental anti-HIV drug that belongs to the class of drugs known as nucleoside reverse transcriptase inhibitors (NRTIs). These drugs interfere with the

  • RDEA806

    RDEA896 is a new NNRTI, developed by Ardea Biosciences, with a high barrier to resistance against the common mutations that develop with efavirenz and nevirapine. A

  • SCH532706

    A 'second-generation' small molecule CCR5 antagonist, SCH532706, boosted with ritonavir, demonstrated potent anti-HIV activity and was generally well-tolerated in a small ten-day monotherapy study according to

  • SPI-452

    SPI-452 from Sequoia Pharmaceuticals is another pharmacokinetic enhancer that, in animal studies, was able to boost levels of the protease inhibitors saquinavir, lopinavir, and atazanavir. In a phase

  • TBR-652

    TBR-652 is a CCR5 antagonist being developed by Tobira Therapeutics. The drug has a half-life in the body of 35 to 40 hours. Phase I

  • TNX-355

    TNX-355, a genetically engineered monoclonal antibody that acts on the CD4 receptor, has shown considerable promise. TNX-355 targets a part of the CD4 receptor that

  • UK-453,061

    UK-453,061 (lersivirine), a Pfizer drug now being developed by ViiV Healthcare, is a second-generation NNRTI. It does not seem to have a significant effect on CYP3A4

  • Vicriviroc (SCH-D)

    Vicriviroc is a CCR5 antagonist originally developed by Schering-Plough’s  and previously known as SCH-D and SCH-417690. Merck & Co., Inc. acquired vicriviroc in its merger with Schering

  • Vivecon (MP-9055)

    According to developer Myriad Genetics MP-9055 (Vivecon), an experimental HIV maturation inhibitor, is entering phase IIA clinical trials in antiretroviral-naive HIV-positive patients.  Completed phase I dose-ranging